The status of pharmacotherapy for autism spectrum disorders

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2007-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.8.11.1579PMID 17685878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study.

  2007cited by this paper
• Oxytocin increases retention of social cognition in autism.

  2007cited by this paper
• Melatonin therapy for circadian rhythm sleep disorders in children with multiple disabilities: what have we learned in the last decade?

  2007cited by this paper
• A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism

  2007cited by this paper
• A retrospective study of memantine in children and adolescents with pervasive developmental disorders

  2007cited by this paper
• Ramelteon for Insomnia in Two Youths with Autistic Disorder

  2006cited by this paper
• The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders.

  2006cited by this paper
• Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders

  2006cited by this paper
• Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations

  2006cited by this paper
• Psychopathology in Adults with Autism and Intellectual Disability

  2006cited by this paper
• A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation

  2006influential reference
• Internet survey of treatments used by parents of children with autism.

  2006cited by this paper
• Oxytocin, vasopressin and pair bonding: implications for autism

  2006cited by this paper
• An update on publicly funded multisite trials in pediatric psychopharmacology.

  2006cited by this paper
• Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.

  2006cited by this paper
• AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders

  2006cited by this paper
• AProspective, Open-Label Trial of Galantamine in Autistic Disorder

  2006cited by this paper
• Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders.

  2006cited by this paper
• An Open-Label Study of Controlled-Release Melatonin in Treatment of Sleep Disorders in Children with Autism

  2006cited by this paper
• ADouble-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive Developmental Disorder

  2006influential reference
• Open-Label Atomoxetine for Attention-Deficit/ Hyperactivity Disorder Symptoms Associated with High-Functioning Pervasive Developmental Disorders

  2006cited by this paper
• Behavioral and Emotional Problems in Young People with Pervasive Developmental Disorders: Relative Prevalence, Effects of Subject Characteristics, and Empirical Classification

  2006cited by this paper
• Topiramate in children with autistic spectrum disorders.

  2006cited by this paper
• Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study

  2006influential reference
• Risperidone and adaptive behavior in children with autism.

  2006cited by this paper
• Autism: a review of the state of the science for pediatric primary health care clinicians.

  2006cited by this paper
• Neuropsychological Effects of Risperidone in Children with Pervasive Developmental Disorders: ABlinded Discontinuation Study

  2006cited by this paper
• Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms.

  2006cited by this paper
• Effect of CX516, an AMPA-Modulating Compound, on Cognition and Behavior in Fragile X Syndrome: AControlled Trial

  2006cited by this paper
• AProspective, Open-Label Trial of Memantine in the Treatment of Cognitive, Behavioral, and Memory Dysfunction in Pervasive Developmental Disorders

  2006cited by this paper
• Compulsive masturbation in infantile autism treated by mirtazapine.

  2006cited by this paper
• Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

  2006cited by this paper
• Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.

  2006cited by this paper
• Clinical Effects and Adverse Reactions of Off-Label Use of Aripiprazole in Children and Adolescents with Developmental Disabilities

  2006cited by this paper
• Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study

  2006influential reference
• Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

  2006influential reference
• Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series

  2006cited by this paper
• Parental Perceptions and Use of Complementary and Alternative Medicine Practices for Children with Autistic Spectrum Disorders in Private Practice

  2006cited by this paper
• Donepezil in the Treatment of ADHD-Like Symptoms in Youths With Pervasive Developmental Disorder

  2006cited by this paper
• Essential Psychopharmacology: The Prescriber’s Guide

  2006cited by this paper
• Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence.

  2006cited by this paper
• Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy

  2006influential reference
• Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot Study

  2006cited by this paper
• Target-symptom psychopharmacology: between the forest and the trees.

  2006cited by this paper
• Psychopathology in Children and Adolescents with Autism Compared to Young People with Intellectual Disability

  2006cited by this paper
• Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.

  2006influential reference
• Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders.

  2006cited by this paper
• Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism.

  2006cited by this paper
• Patterns of Complementary and Alternative Medical Therapy Use in Children Diagnosed with Autism Spectrum Disorders

  2006cited by this paper
• Oral Human Immunoglobulin for Children with Autism and Gastrointestinal Dysfunction: A Prospective, Open-Label Study

  2006cited by this paper
• Pediatric bipolar disorder: emerging diagnostic and treatment approaches.

  2006cited by this paper
• Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.

  2006cited by this paper
• The Use of Selective Serotonin Reuptake Inhibitors in Autism and Related Disorders

  2006influential reference
• Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder.

  2005influential reference
• Clinical Efficacy of Fluvoxamine and Functional Polymorphism in a Serotonin Transporter Gene on Childhood Autism

  2005influential reference
• Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.

  2005cited by this paper
• Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome.

  2005cited by this paper
• Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder.

  2005cited by this paper
• Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.

  2005cited by this paper
• Prepubertal bipolar disorder: available pharmacological treatment options

  2005cited by this paper
• Safety issues with drug therapies for autism spectrum disorders.

  2005cited by this paper
• The case for practical clinical trials in psychiatry.

  2005cited by this paper
• Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders.

  2005cited by this paper
• The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary.

  2005cited by this paper
• Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.

  2005cited by this paper
• Comparison of DSM-IV symptoms in elementary school-age children with PDD versus clinic and community samples

  2005cited by this paper
• Intravenous secretin for autism spectrum disorder.

  2005cited by this paper
• Inositol treatment of autism

  2005cited by this paper
• Tetrahydrobiopterin in the Treatment of Children With Autistic Disorder: A Double-blind Placebo-Controlled Crossover Study

  2005influential reference
• An open-label trial of escitalopram in pervasive developmental disorders.

  2005cited by this paper
• Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials.

  2005cited by this paper
• ADouble-Blind, Placebo-Controlled Study of Valproate for Aggression in Youth with Pervasive Developmental Disorders

  2005influential reference
• Medication Patterns in Patients with Autism: Temporal, Regional, and Demographic Influences

  2005cited by this paper
• The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders

  2005cited by this paper
• Novel treatments for autistic spectrum disorders.

  2005cited by this paper
• Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.

  2005cited by this paper
• Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

  2005cited by this paper
• Treatment Incidence and Patterns in Children and Adolescents with Autism Spectrum Disorders

  2005cited by this paper
• Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.

  2005cited by this paper
• A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive Behaviors in Childhood and Adolescent Autism

  2005influential reference
• Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders

  2005cited by this paper
• Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders

  2005cited by this paper
• Methylphenidate for Pervasive Developmental Disorders: Safety and Efficacy of Acute Single Dose Test and Ongoing Therapy: An Open-Pilot Study

  2004cited by this paper
• Treating Functional Impairment of Autism with Selective Serotonin-Reuptake Inhibitors

  2004influential reference
• Neurologic treatment strategies in autism: an overview of medical intervention strategies.

  2004cited by this paper
• Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.

  2004cited by this paper
• Impact of Recent Findings on Study Design of Future Autism Clinical Trials

  2004cited by this paper
• Nonpharmacologic treatments for pediatric sleeplessness.

  2004cited by this paper
• Trajectory of development in adolescents and adults with autism.

  2004cited by this paper
• A pilot study of D-cycloserine in subjects with autistic disorder.

  2004cited by this paper
• Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.

  2004cited by this paper
• Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

  2004cited by this paper
• Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis.

  2004cited by this paper
• Sleep disorders, epilepsy, and autism.

  2004cited by this paper
• Melatonin therapy for circadian rhythm sleep disorders in children with multiple disabilities: what have we learned in the last decade?

  2004cited by this paper
• Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.

  2004cited by this paper
• Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders

  2004influential reference
• Subject Selection and Characterization in Clinical Trials in Children with Autism

  2004cited by this paper
• Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

  2004cited by this paper
• Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis.

  2004cited by this paper

• A Review of Management Strategies for Aggression and Self-Injury in Youth With Autism Spectrum Disorder.

  2026cites this paper
• A Review of the Lived Experiences and Psychosocial and School Outcomes of Latinx Childhood Cancer Survivors With a Focus on Cultural Considerations

  2025cites this paper
• Efficacy and safety of risperidone and aripiprazole in reducing severity of irritability in children with autism spectrum disorder: A randomized controlled trial.

  2025cites this paper
• Disruptive ecotoxicological effects of fluoxetine on serotoninergic signaling and enteric neurogenesis in early zebrafish larvae (Danio rerio).

  2025cites this paper
• Predictors of Psychotropic Medication Use Among Autistic Adults.

  2025cites this paper
• Prevalence Trends and Treatment Patterns of Autism Spectrum Disorder Among Children and Adolescents in the United States from 2017 to 2020

  2024cites this paper
• Trends in ASD Pharmacological Research: An Analysis of ClinicalTrials.gov

  2022cites this paper
• A cross-sectional study of community pharmacists' self-reported disease knowledge and competence in the treatment of childhood autism spectrum disorder

  2022cites this paper
• Sensitivity and specificity of DSM-5 diagnostic criteria for autism spectrum disorder in a child and adolescent sample.

  2021cites this paper
• Many Young Children with Autism Who Use Psychotropic Medication Do Not Receive Behavior Therapy: A Multisite Case-Control Study.

  2021cites this paper
• Refractoriness of aggressive behaviour to pharmacological treatment: cortical thickness analysis in autism spectrum disorder

  2020cites this paper
• Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta‐analysis

  2019cites this paper
• Sensitivity and specificity of DSM-5 diagnostic criteria for autism spectrum disorder in a child and adolescent sample.

  2019cites this paper
• Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder

  2018influential citation
• Autism Spectrum Disorder

  2018cites this paper
• Polypharmacy and Autism 1 Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder

  2017cites this paper
• Efficacité et tolérance de la clozapine sur les comportements-défis des patients adultes présentant un trouble du spectre de l’autisme

  2017cites this paper
• La prescription de psychotropes chez les adultes avec Trouble du Spectre de l’Autisme : état des connaissances et étude descriptive

  2017cites this paper
• Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder

  2017cites this paper
• A review of how psychotropic medication can affect the motivation of challenging behavior

  2016cites this paper
• Autism Spectrum Disorders among Adults: Burden of Healthcare Services' Utilization and Expenditures

  2016cites this paper
• Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis

  2016cites this paper
• Impact of employee benefits on families with children with autism spectrum disorders

  2016cites this paper
• Aberrant Behaviors and Co-occurring Conditions as Predictors of Psychotropic Polypharmacy among Children with Autism Spectrum Disorders

  2015cites this paper
• Parent Perspectives on Psychotropic Medication Use and Interactions With Prescribing Health Care Providers Among Adolescents and Adults With an Autism Spectrum Disorder

  2015cites this paper
• The effect of prenatal valproic acid exposure on the developing brain : face, construct, and predictive validity of an animal model of autism

  2015cites this paper
• The use of antipsychotics in preschoolers: A veto or a sensible last option?

  2014cites this paper
• Therapeutic approaches for shankopathies

  2014cites this paper
• Mental Health Services for Individuals with High Functioning Autism Spectrum Disorder

  2014cites this paper
• Child, Parent, and Service Predictors of Psychotropic Polypharmacy Among Adolescents and Young Adults with an Autism Spectrum Disorder

  2014cites this paper
• Rates and Predictors of Adherence to Psychotropic Medications in Children with Autism Spectrum Disorders

  2014cites this paper
• GENETIC ASPECTS OF AUTISM SPECTRUM DISORDERS

  2014cites this paper
• Repetitive Transcranial Magnetic Stimulation as a possible new treatment strategy to improve social skills in Autism Spectrum Disorder

  2014cites this paper
• Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review

  2014cites this paper
• Developing zebrafish models of autism spectrum disorder (ASD).

  2014cites this paper
• Effectiveness and Tolerability of Switching to Aripiprazole From Risperidone in Subjects With Autism Spectrum Disorders: A Prospective Open-Label Study

  2013cites this paper
• Efficacy of Atomoxetine for the Treatment of ADHD Symptoms in Patients With Pervasive Developmental Disorders

  2013cites this paper
• Autismo y trastorno por déficit de atención/hiperactividad: intervención farmacológica

  2013cites this paper
• Mass spectrometry as a tool for studying autism spectrum disorder

  2013cites this paper
• Evidence review and clinical guidance for the use of ziprasidone in Canada

  2013cites this paper
• [Neuroanatomical, genetic and neurochemical aspects of infantile autism].

  2013cites this paper
• Anxiety in Children with Autism Spectrum Disorder

  2013cites this paper
• [Autism and attention deficit hyperactivity disorder: pharmacological intervention].

  2013cites this paper
• Atomoxetine for Treating ADHD Symptoms in Autism

  2013cites this paper
• Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.

  2012cites this paper
• Oxidative stress-related biomarkers in autism: systematic review and meta-analyses.

  2012cites this paper
• Polypharmacy profiles and predictors among adults with autism spectrum disorders

  2012cites this paper
• How could clock gene variants contribute to the causes of autism

  2011cites this paper
• Autism Spectrum Disorders: Comorbid Psychopathology and Treatment

  2011cites this paper
• Management of Symptoms in Children With Autism Spectrum Disorders: A Comprehensive Review of Pharmacologic and Complementary-Alternative Medicine Treatments

  2011cites this paper
• Environmental Factors in the Aetiology of Autism – Lessons from Animals Prenatally Exposed to Valproic Acid

  2011cites this paper
• Reporting of medication information in applied studies of people with autism

  2011cites this paper
• Psychotropic drug efficacy and side effects for persons with autism spectrum disorders

  2011cites this paper
• Comparing residential programmes for adults with autism spectrum disorders and intellectual disability: outcomes of challenging behaviour and quality of life.

  2011cites this paper
• Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.

  2010cites this paper
• THE IDENTIFICATION OF CANDIDATE GENES USING cDNA MICROARRAY AND THE ANALYSIS OF TWO SNPs OF THE REELIN GENE IN A SOUTH AFRICAN AUTISTIC POPULATION

  2010cites this paper
• Access to Dental Care for a Selected Group of Children and Adolescents with ASD

  2010cites this paper
• Pharmacological management of core and comorbid symptoms in autism-spectrum disorder

  2010cites this paper
• Autism-spectrum disorders are one of the leading causes of lifetime developmental disability ( Fombonne

  2010cites this paper
• Primary care for children with autism.

  2010cites this paper
• Development of G-quadruplex Stabilizers as Anticancer Drug Therapy and Selective Agonists of the Human Oxytocin Receptor as a Therapeutic Tool for Neuropsychiatric Disorders

  2010cites this paper
• Psychotropic Drug Treatments for People with Autism and Other Developmental Disorders: A Primer for Practicing Behavior Analysts

  2010cites this paper
• Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

  2010cites this paper
• Citalopram not effective for repetitive behaviour in autistic spectrum disorders

  2010cites this paper
• Oxidative pathways as a drug target for the treatment of autism

  2010cites this paper
• A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders

  2009cites this paper
• Autism: an emerging ‘neuroimmune disorder’ in search of therapy

  2009cites this paper
• Atypical and Typical Antipsychotics in the Schools.

  2009cites this paper
• Mecamylamine – a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders

  2009cites this paper
• Management of autism spectrum disorders in primary care.

  2009cites this paper
• Autism, gut-blood-brain barrier, and mast cells.

  2008cites this paper
• A review of recent reports on autism: 1000 studies published in 2007.

  2008cites this paper
• Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment

  2008cites this paper
• Treating pediatric patients with antipsychotic drugs: balancing benefits and safety.

  2008cites this paper
• Management of Children With Autism Spectrum Disorders

  2007cites this paper
• Effectiveness of Highly Active Antiretroviral Therapy in HIV-Positive Children: Evaluation at 12 Months in a Routine Program in Cambodia

  2007cites this paper
• ADouble-Blind, Placebo-Controlled Study of Valproate for Aggression in Youth with Pervasive Developmental Disorders

  2005cites this paper